Global Myasthenia Gravis Market Size, Share, Industry Analysis, Growth Trends and Forecast Report 2026

Western Market Research Predicts that Myasthenia Gravis Market was valued at approximately USD 1.72 billion in 2025 and is expected to reach around USD 3.21 billion by the year 2032, growing at a CAGR of 9.5% globally .

Global Myasthenia Gravis Market Overview

The Global Myasthenia Gravis Market Report 2026 provides an extensive industry analysis covering development components, patterns, flows, and sizes. This report calculates present and past market values to forecast potential market management through the forecast period between 2026-2032. This research study involved the extensive usage of both primary and secondary data sources, including the study of various parameters affecting the industry, such as government policy, market environment, competitive landscape, historical data, present trends, technological innovation, and the technical progress in related industries .

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. It is caused by a breakdown in the normal communication between nerves and muscles, often due to antibodies blocking or destroying acetylcholine receptors at the neuromuscular junction . The condition affects individuals across all age groups, with increasing prevalence in the aging population .

Impact of COVID-19 on Myasthenia Gravis Market

Since the COVID-19 virus outbreak in December 2019, the disease spread to almost every country globally. The global impacts of the coronavirus disease 2019 (COVID-19) significantly affected the Myasthenia Gravis market in 2020. The pandemic initially caused disruptions in clinical trials, delays in diagnosis and treatment initiation, and concerns about immunosuppressed patients' vulnerability to infection . However, it subsequently accelerated the adoption of telemedicine, remote patient monitoring, and digital health solutions for managing chronic conditions. The crisis also highlighted the importance of targeted immunotherapies and biologics, driving continued investment in MG research and development .

Global Myasthenia Gravis Market Segmentation

The market is segmented by treatment type, drug class, diagnosis, end-user, and distribution channel to provide a detailed view of the industry landscape .

By Treatment Type :

• Drug Treatment: The dominant segment, encompassing various pharmacological approaches:

  • Cholinesterase Inhibitors (e.g., Pyridostigmine): First-line symptomatic treatment improving neuromuscular transmission.

  • Corticosteroids (e.g., Prednisone): Broad immunosuppression for disease control.

  • Immunosuppressants (e.g., Azathioprine, Mycophenolate, Cyclosporine): Long-term disease management.

  • Monoclonal Antibodies: Targeted biologics including complement inhibitors (Soliris, Ultomiris, Zilbrysq) and FcRn inhibitors (Vyvgart, Rystiggo, Imaavy).

  • Rapid Immunotherapies: Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg).

• Therapies:

  • Plasmapheresis (Plasma Exchange): Rapid removal of pathogenic antibodies.

  • Intravenous Immunoglobulin (IVIg): Immunomodulation for acute exacerbations.

• Surgery:

  • Thymectomy: Surgical removal of the thymus gland, which can induce remission in certain patients.

By Drug Class (Detailed) :

• Cholinesterase Inhibitors

• Corticosteroids

• Immunosuppressants

• Intravenous Immunoglobulins (IVIg)

• Monoclonal Antibodies

  • Complement Inhibitors (C5)

  • FcRn Inhibitors

By Diagnosis :

• Blood Test (Antibody Testing: AChR, MuSK, LRP4)

• Edrophonium Test

• Repetitive Nerve Stimulation

• Single-fiber Electromyography (EMG)

• Other Diagnostic Methods

By End-User :

• Hospitals: The largest segment, providing comprehensive care including diagnosis, acute management, and infusion therapies.

• Specialty Clinics: Neurology and neuromuscular centers offering specialized outpatient care.

• Homecare: Growing segment for subcutaneous biologics and self-administered therapies.

• Other Healthcare Facilities: Ambulatory surgical centers and long-term care facilities.

By Distribution Channel :

• Hospital Pharmacies: Dominant channel for IV therapies and biologics requiring medical supervision.

• Retail Pharmacies: Oral medications for chronic management.

• Online Pharmacies/E-Commerce: Emerging channel for convenience and accessibility.

Regional Analysis 

• North America (U.S., Canada, Mexico): The largest market, accounting for approximately 42-45% of global revenue. The U.S. market alone was valued at approximately USD 733 million in 2024. Dominance driven by advanced healthcare infrastructure, high adoption of novel biologics, strong R&D investment, favorable regulatory environment (FDA orphan drug designations, priority reviews), and robust reimbursement frameworks. Major clinical research and key market players are concentrated in this region .

• Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe): The second-largest market, characterized by strong healthcare systems, increasing awareness of rare diseases, supportive government initiatives, and growing adoption of targeted therapies. Germany, France, and the UK lead in market share, with well-established neuromuscular care networks and participation in clinical trials .

• Asia-Pacific (China, India, Japan, South Korea, Australia, Southeast Asia): The fastest-growing region, projected to witness the highest CAGR during the forecast period. Growth fueled by large patient populations, improving healthcare infrastructure, rising healthcare expenditure, increasing awareness of autoimmune disorders, growing medical tourism, and expanding clinical trial activity. China and India represent massive potential markets with increasing diagnosis rates and access to biologic therapies .

• South America (Brazil, Argentina, Rest of South America): Emerging market with growth potential driven by improving healthcare access, increasing awareness, and gradual adoption of advanced diagnostics and treatments in major urban centers .

• Middle East & Africa (GCC, South Africa, Egypt, Rest of MEA): Developing market with opportunities from healthcare infrastructure investments, growing focus on rare disease management, and increasing availability of specialized care in Gulf countries and South Africa .

Porter's Five Forces Analysis 

• Threat of New Entrants (Moderate): High barriers due to substantial R&D investment requirements, complex regulatory pathways, need for specialized expertise in biologics development, and intellectual property protections. However, attractive market growth and orphan drug incentives continue to attract specialized biotechnology companies.

• Bargaining Power of Buyers (Moderate): Patients and healthcare providers have limited options for rare disease treatments, but increasing competition among biologics is expanding choices. Payers (insurance companies, government programs) exert significant pressure on pricing and reimbursement, particularly for high-cost biologics.

• Bargaining Power of Suppliers (Low to Moderate): Multiple suppliers of raw materials, contract research organizations (CROs), and contract manufacturing organizations (CMOs) exist. However, specialized biologic manufacturing capabilities are concentrated among fewer providers.

• Threat of Substitutes (Moderate): Traditional immunosuppressants and corticosteroids remain alternatives, but targeted biologics offer superior efficacy and safety profiles. Different biologic classes (complement inhibitors vs. FcRn inhibitors) compete with each other, and biosimilars are emerging (e.g., Soliris biosimilars in 2025) .

• Intensity of Rivalry (High): The market has become increasingly competitive with multiple approved biologics (argenx's Vyvgart, UCB's Zilbrysq and Rystiggo, AstraZeneca's Soliris and Ultomiris, J&J's Imaavy) and a robust pipeline. Competition focuses on efficacy, safety, convenience (subcutaneous vs. IV), and pricing .

SWOT Analysis 

• Strengths:

  • Transformative shift toward targeted biologic therapies with improved efficacy and safety profiles.

  • Strong regulatory support through orphan drug designations, priority reviews, and fast-track approvals.

  • Growing understanding of disease pathophysiology enabling precision medicine approaches.

  • Established diagnostic methods with high sensitivity (e.g., blood tests detecting AChR antibodies in 85-90% of patients).

  • Increasing patient advocacy and awareness driving diagnosis and treatment rates.

• Weaknesses:

  • High cost of biologic therapies limiting access in emerging markets and creating reimbursement challenges.

  • Delayed diagnosis due to symptom overlap with other neurological conditions.

  • Limited availability of neuromuscular specialists in rural and underserved areas.

  • Lack of curative treatments; current options focus on symptom management.

  • Potential side effects of long-term immunosuppression with conventional therapies.

• Opportunities:

  • Expanding indications for existing biologics into broader patient populations (e.g., seronegative MG).

  • Development of novel mechanisms of action (FcRn inhibitors, complement inhibitors, B-cell modulators).

  • Convenience-enhancing formulations (subcutaneous, oral) improving patient compliance.

  • Emerging markets with improving healthcare infrastructure and increasing diagnosis rates.

  • Digital health integration for remote monitoring and personalized treatment adjustment.

  • Biosimilar development potentially reducing costs and improving access .

• Threats:

  • Intense competition among multiple approved biologics leading to pricing pressure.

  • Reimbursement challenges and cost-containment measures by healthcare payers.

  • Potential safety concerns with long-term use of novel biologics.

  • Stringent regulatory requirements across different regions.

  • Small patient populations limiting commercial scale.

  • Pipeline failures in late-stage clinical development.

Trend Analysis 

• FcRn Inhibitor Revolution: A major trend is the clinical transition to neonatal Fc receptor (FcRn) blockade, which selectively reduces pathogenic IgG autoantibodies without global immunosuppression. FcRn blockers like Vyvgart (efgartigimod) and Rystiggo (rozanolixizumab) have demonstrated significant efficacy with favorable safety profiles, creating a new standard for disease modification .

• Convenience-Focused Innovation: The market is shifting toward subcutaneous formulations and self-administration options, reducing healthcare system burden and improving patient quality of life. Vyvgart Hytrulo's pre-filled syringe formulation and Zilbrysq's self-administered daily subcutaneous injection exemplify this trend .

• Expanding Biologic Pipeline: Numerous investigational drugs targeting novel mechanisms (oral complement inhibitors, bispecific antibodies, B-cell modulators, CAR T-cell therapies) are in late-stage development, promising further therapeutic differentiation and options for refractory patients .

• Precision Medicine Approaches: Growing focus on biomarker-based patient stratification and personalized treatment algorithms based on antibody status, disease severity, and genetic factors. This enables more targeted and effective treatment strategies .

• Digital Health Integration: Adoption of telemedicine, remote monitoring platforms, and digital therapeutics for MG management. MGteam's specialized digital platform and partnerships like Huma-UCB collaboration exemplify this trend .

• Biosimilar Entry: The introduction of Soliris biosimilars (Bkemv, Epysqli) in 2025 is reshaping the competitive landscape, potentially improving access and reducing costs .

Drivers & Challenges 

Drivers:

• Increasing Prevalence and Diagnosis Rates: Rising incidence of autoimmune disorders, growing geriatric population vulnerable to MG, and improved diagnostic techniques are expanding the patient population. Global prevalence is estimated at 150-200 cases per million, with approximately 700,000 affected individuals worldwide .

• Clinical Adoption of Targeted Biologics: Superior efficacy and safety of monoclonal antibodies (complement inhibitors, FcRn inhibitors) compared to conventional therapies are driving rapid adoption, particularly for moderate to severe generalized MG .

• Favorable Regulatory Environment: Orphan drug designations, breakthrough therapy designations, priority reviews, and accelerated approvals from FDA and EMA encourage R&D investment and accelerate market entry of novel therapies .

• Growing Healthcare Expenditure: Increasing healthcare spending, particularly in developed regions, supports access to expensive biologic therapies. U.S. health spending reached $4.5 trillion in 2022, supporting advanced treatment adoption .

• Patient Advocacy and Awareness: Rare disease organizations and patient groups are driving awareness, supporting early diagnosis, and advocating for favorable reimbursement policies .

Challenges:

• High Cost of Biologic Therapies: Prohibitively expensive treatments create access barriers for patients and healthcare systems, particularly in low- and middle-income countries. Reimbursement negotiations and cost-containment measures limit market penetration .

• Diagnostic Delays and Underdiagnosis: Symptom overlap with other neuromuscular disorders, limited awareness among healthcare professionals, and lack of specialized neurologists in some regions lead to delayed or missed diagnosis .

• Limited Long-Term Safety Data: Evolving safety profiles of novel biologics require ongoing post-marketing surveillance, and uncertainty may limit adoption until more robust real-world evidence accumulates .

• Complex Treatment Algorithms: Heterogeneous disease presentation and variable response to therapies complicate treatment decisions and standardization of care guidelines .

Value Chain Analysis 

1. Research and Discovery: Basic research into MG pathophysiology, target identification, and drug discovery at academic institutions, research organizations, and pharmaceutical companies. Government funding and venture capital support early-stage innovation.

2. Preclinical Development: Lead optimization, pharmacology studies, toxicology assessments, and manufacturing process development for candidate molecules.

3. Clinical Development: Phase I-III clinical trials establishing safety and efficacy. Increasing globalization of trials with sites in North America, Europe, and Asia-Pacific. Regulatory interactions for study design and approval.

4. Regulatory Approval: Submission of marketing applications to FDA, EMA, PMDA, NMPA, and other regulatory authorities. Orphan drug designations and priority reviews expedite approvals.

5. Manufacturing: Production of active pharmaceutical ingredients (APIs) and finished dosage forms. Biologics require specialized cell culture, purification, and formulation facilities with stringent quality control.

6. Distribution and Logistics: Cold chain management for biologics, distribution through specialty pharmacies, hospital networks, and wholesalers. Inventory management and traceability systems.

7. Marketing and Sales: Physician education, patient awareness campaigns, key opinion leader engagement, and market access strategies including pricing and reimbursement negotiations.

8. Post-Marketing Surveillance: Phase IV studies, real-world evidence generation, safety monitoring, and label expansion studies for additional indications or formulations.

Top Key Players Covered in Myasthenia Gravis Market 

• argenx SE (Netherlands/USA) - Vyvgart, Vyvgart Hytrulo (efgartigimod)

• UCB Pharma (Belgium) - Zilbrysq (zilucoplan), Rystiggo (rozanolixizumab)

• AstraZeneca (UK) - Soliris (eculizumab), Ultomiris (ravulizumab) (via Alexion acquisition)

• Johnson & Johnson (USA) - Imaavy (nipocalimab)

• Regeneron Pharmaceuticals (USA) - cemdisiran (pipeline)

• Novartis AG (Switzerland) - Fabhalta (iptacopan) (pipeline)

• F. Hoffmann-La Roche Ltd (Switzerland) - IVIg, pipeline candidates

• CSL Behring (USA/Germany) - IVIg, subcutaneous Ig

• Grifols S.A. (Spain) - IVIg, plasma-derived therapies

• Takeda Pharmaceutical Company (Japan) - IVIg, immunoglobulin therapies

• Amgen Inc. (USA) - Bkemv (Soliris biosimilar)

• Teva Pharmaceuticals (Israel) - Epysqli (Soliris biosimilar)

• RemeGen Co. Ltd. (China) - Telitacicept

• Immunovant Inc. (USA) - batoclimab (pipeline)

• Harbour BioMed (China/Netherlands) - pipeline candidates

• Pfizer Inc. (USA) - immunosuppressants

• AbbVie Inc. (USA) - immunosuppressants

• Mitsubishi Tanabe Pharma (Japan) - IVIg, plasma products

• Baxter International (USA) - IVIg, infusion therapies

• Horizon Therapeutics (USA) - pipeline (acquired by Amgen)

• Cartesian Therapeutics (USA) - Descartes-08 (CAR T-cell therapy pipeline)

• Cabaletta Bio (USA) - CABA-201 (CAR T-cell therapy pipeline)

Quick Recommendations for Stakeholders

• For Manufacturers: Invest in differentiated mechanisms of action and convenience-enhancing formulations (subcutaneous, oral) to compete in an increasingly crowded biologic market. Develop robust real-world evidence programs demonstrating long-term safety and efficacy. Pursue label expansion strategies into broader patient populations (seronegative MG, earlier lines of therapy). Build patient support programs and digital health tools to enhance adherence and outcomes. Prepare for biosimilar competition through lifecycle management and next-generation products .

• For Investors: Target companies with strong pipeline differentiation, first-in-class or best-in-class potential, and clear commercial strategies in the MG space. Monitor clinical trial results for emerging mechanisms (oral complement inhibitors, CAR T-cell therapies). Assess reimbursement strategies and market access capabilities as key success factors. Consider opportunities in emerging markets with growing patient populations and improving healthcare infrastructure .

• For Healthcare Providers: Develop institutional protocols for integrating novel biologics into treatment algorithms based on patient characteristics (antibody status, disease severity, comorbidities). Establish multidisciplinary care teams including neurologists, infusion nurses, and patient navigators. Utilize telemedicine and remote monitoring tools to optimize disease management and reduce hospitalizations. Stay informed about emerging therapies and evolving treatment paradigms through continuing education and guideline updates .

• For New Entrants: Focus on niche, high-unmet-need segments such as refractory patients, specific serotypes (MuSK+, LRP4+, seronegative), or pediatric populations. Develop novel mechanisms of action or combination approaches offering differentiation from established biologics. Leverage regulatory incentives (orphan drug, breakthrough therapy) to accelerate development. Consider strategic partnerships with established players for commercialization and market access. Build patient-centric development programs incorporating patient-reported outcomes and real-world evidence .